Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Name: Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
Published: 2020
License: Public Domain

R-Pharm International, LLC · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

coronavirus sars-cov-2

covid-19, sars-cov-2, severe acute respiratory syndrome coronavirus 2, 2019-ncov, 2019 novel coronavirus, respiratory disease, lung disease, coronavirus, interventional, phase2, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Related documents